Astrana Health, Inc. (NASDAQ:ASTH) Receives Consensus Recommendation of “Moderate Buy” from Brokerages

Astrana Health, Inc. (NASDAQ:ASTH) has been assigned an average recommendation of “Moderate Buy” from the nine analysts that are covering the company, Marketbeat.com reports. Two investment analysts have rated the stock with a hold recommendation, six have assigned a buy recommendation and one has issued a strong buy recommendation on the company. The average 12 month target price among brokerages that have issued ratings on the stock in the last year is $56.17.

Several equities research analysts have issued reports on ASTH shares. Stifel Nicolaus decreased their price target on shares of Astrana Health from $70.00 to $56.00 and set a “buy” rating on the stock in a research note on Thursday, February 20th. Truist Financial dropped their target price on Astrana Health from $50.00 to $46.00 and set a “buy” rating for the company in a research note on Tuesday, March 18th. Macquarie raised shares of Astrana Health to a “hold” rating in a research report on Monday, December 16th. Bank of America dropped their price objective on Astrana Health from $55.00 to $49.00 and set a “buy” rating for the company in a report on Tuesday, March 4th. Finally, Robert W. Baird reduced their price target on shares of Astrana Health from $86.00 to $50.00 and set an “outperform” rating on the stock in a research report on Monday, March 3rd.

Astrana Health Stock Up 1.5 %

Shares of NASDAQ ASTH opened at $31.01 on Thursday. The firm’s 50-day moving average is $33.77 and its two-hundred day moving average is $41.75. The company has a market capitalization of $1.55 billion, a PE ratio of 23.85, a price-to-earnings-growth ratio of 1.37 and a beta of 1.30. Astrana Health has a 12-month low of $23.12 and a 12-month high of $63.20. The company has a debt-to-equity ratio of 0.60, a current ratio of 1.91 and a quick ratio of 1.91.

Astrana Health (NASDAQ:ASTH) last posted its earnings results on Thursday, February 27th. The company reported ($0.15) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.22 by ($0.37). The company had revenue of $665.21 million during the quarter, compared to analysts’ expectations of $617.24 million. Astrana Health had a net margin of 3.63% and a return on equity of 9.37%. Equities analysts anticipate that Astrana Health will post 1.15 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the business. Pilgrim Partners Asia Pte Ltd purchased a new stake in Astrana Health during the 4th quarter worth approximately $40,000. Quarry LP grew its position in shares of Astrana Health by 35.5% during the fourth quarter. Quarry LP now owns 1,799 shares of the company’s stock worth $57,000 after buying an additional 471 shares in the last quarter. KBC Group NV increased its stake in shares of Astrana Health by 108.4% in the fourth quarter. KBC Group NV now owns 2,530 shares of the company’s stock worth $80,000 after buying an additional 1,316 shares during the last quarter. Quest Partners LLC acquired a new stake in Astrana Health in the third quarter valued at $133,000. Finally, US Bancorp DE boosted its stake in Astrana Health by 3,880.0% during the 4th quarter. US Bancorp DE now owns 4,776 shares of the company’s stock valued at $151,000 after acquiring an additional 4,656 shares during the last quarter. Institutional investors and hedge funds own 52.77% of the company’s stock.

About Astrana Health

Astrana Health, Inc, Inc, a physician-centric technology-powered healthcare management company, provides medical care services in the United States. It operates through three segments: Care Partners, Care Delivery, and Care Enablement. The company is leveraging its proprietary population health management and healthcare delivery platform, operates an integrated, value-based healthcare model which empowers the providers in its network to deliver care to its patients.